AccessibilityHelpAbout Us

Vogenx(NASDAQ) VOGX

Market Cap$438.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+127%
5 YearN/A
1 YearN/A
1 Month-0%
$29.34
-9.72%
-3.16Today
After hours$29.49+$0.15 (+0.51%)
Vogenx last closing stock price
MetricPriceDate
Last closeUSD 29.502026-09-21
Vogenx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.01%USD 32.422026-09-14
1 month-0.07%USD 29.522026-08-21
Since inception+126.92%USD 13.002026-08-12

Vogenx Financials at a Glance

Market Cap

$438.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.51

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.51 (Low)

Price

$29.34

Volume

245,849

Open

$31.59

Previous Close

$29.50

Daily Range

$28.30 - $33.82

52-Week Range

$12.95 - $38.41

Estimated Earnings Date

Dec 2, 2026

VOGX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vogenx

Vogenx Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for serious metabolic diseases. The company focuses on conditions such as post-bariatric hypoglycemia and gastroparesis, with its lead product candidate being mizagliflozin.

Products and Services
  • Mizagliflozin: An oral drug candidate targeting post-bariatric hypoglycemia
  • Research and development of therapies for gastroparesis
  • Exploration of treatments for GIP-dependent Cushing's Syndrome
Growth Outlook
  • Strong market potential in the biopharmaceutical sector for metabolic disorders
  • Increasing prevalence of conditions like gastroparesis and PBH
  • Ongoing clinical trials expected to enhance product pipeline visibility
Financial Highlights
  • Market capitalization of approximately $450.8 million
  • Stock price range between $12.95 and $35.5 over the past year
  • Average trading volume of 229,331 shares, indicating investor interest
Vogenx Inc. operates in the biotechnology industry, focusing on unmet medical needs in human metabolism. The company is positioned to capitalize on the growing demand for effective treatments in this area. With a solid market capitalization and a significant stock price range, Vogenx Inc. demonstrates potential for growth and investor interest. The ongoing clinical trials and research initiatives may further enhance the company's product offerings and market presence.
AI Generated • Sep 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

James Green, MBA

Website

www.vogenx.com

Headquarters

Raleigh, NC 27609, US

VOGX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$438.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.86M

Volume

245.85K

Avg. Volume

219.42K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Vogenx Performance Analysis

Vogenx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vogenx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.15N/A
20252025-12-31USD -0.10-34.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$438.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

5

N/A

Net Income

-$0.38

N/A

EBITDA

-$0.36

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.06

N/A

Total Debt

$0.87

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.87

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

$0.03

N/A

Operating Cash Flow

$0.03

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,763.63+0.01%
^DJIDJI
$52,032.71+0.01%
^IXICNASDAQ
$27,092.05+0.02%
BTCBitcoin
$85,915.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About VOGX

What is the current price of Vogenx?

Vogenx is trading at $29.50 per share.

What is the 52-week range for Vogenx?

Over the past 52 weeks, Vogenx has traded between $12.95 and $38.41.

How much debt does Vogenx have?

As of the most recent reporting period, Vogenx reported total debt of $867.70K.

How much cash does Vogenx have on hand?

Vogenx reported $193.02K in cash and cash equivalents in its most recent financial results.

What is Vogenx’s dividend yield?

Vogenx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services